With 0.51 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.59 million shares. During the session, the Diagnostics & Research company that operates in wider Healthcare sector, reached to the highest price of $436.05 whereas the lowest price it dropped to was $425.1553. The 52-week range on IDXX shows that it touched its highest point at $583.39 and its lowest point at $398.50 during that stretch. It currently has a 1-year price target of $495.73. Beta for the stock currently stands at 1.37.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of IDXX was up-trending over the past week, with a rise of 1.36%, but this was up by 2.77% over a month. Three-month performance dropped to -9.50% while six-month performance fell -14.13%. The stock lost -17.62% in the past year, while it has lost -22.98% so far this year. A look at the trailing 12-month EPS for IDXX yields 10.36 with Next year EPS estimates of 11.98. For the next quarter, that number is 2.40. This implies an EPS growth rate of 3.94% for this year and 14.59% for next year. EPS is expected to grow by 13.00% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 18.76%.
Float and Shares Shorts:
At present, 82.04 million IDXX shares are outstanding with a float of 81.08 million shares on hand for trading. On 2024-11-15, short shares totaled 1.62 million, which was 198.00000000000003 higher than short shares on 1728950400. In addition to Mr. Jonathan J. Mazelsky as the firm’s President, CEO & Director, Mr. Brian P. McKeon serves as its CFO, Executive VP & Treasurer.
Institutional Ownership:
Through their ownership of 0.94341004 of IDXX’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-09-30, IDXX reported revenue of $975543000.0 and operating income of $303892000.0. The EBITDA in the recently reported quarter was $340739000.0 and diluted EPS was $2.8.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for IDXX since 6 analysts follow the stock currently. There are 6 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With IDXX analysts setting a high price target of 566.0 and a low target of 400.0, the average target price over the next 12 months is 478.5477. Based on these targets, IDXX could surge 32.4% to reach the target high and fall by -6.43% to reach the target low. Reaching the average price target will result in a growth of 11.94% from current levels.
Analysts have provided yearly estimates in a range of $10.50628 being high and $10.40602 being low. For IDXX, this leads to a yearly average estimate of $10.45615.
